Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157723 | 0.92 | NPSR1 (0.50) | NPSR1KDM4ERXFP1MEN1KMT2A | |
| SCHEMBL2158693 | 0.84 | PTPN1 (0.60) | NPSR1KDM4ERXFP1MEN1KMT2A | |
| SCHEMBL3814765 | 0.84 | MEN1 (0.44) | NPSR1KDM4ERXFP1MEN1KMT2A | |
| SCHEMBL2158090 | 0.81 | MEN1 (0.50) | NPSR1KDM4ERXFP1MEN1KMT2A | |
| SCHEMBL2158495 | 0.80 | NPSR1 (0.57) | NPSR1KDM4ERXFP1 | |
| SCHEMBL2157725 | 0.80 | NPSR1 (0.56) | NPSR1KDM4ERXFP1 | |
| SCHEMBL6426603 | 0.79 | NPSR1 (0.60) | NPSR1KDM4ERXFP1 | |
| SCHEMBL2158232 | 0.78 | NPSR1 (0.61) | NPSR1KDM4ERXFP1 | |
| SCHEMBL2157697 | 0.78 | NPSR1 (0.55) | NPSR1KDM4ERXFP1 | |
| SCHEMBL2157751 | 0.78 | NPSR1 (0.53) | NPSR1KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | NPSR1 10/4885KDM4E 3848/4885RXFP1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.